EnglishעבריתEspañol
🌍 Worldwide🩺 Medicine & Health📡 OpenAlex🕒 Updated November 2, 2026

Most-Cited CRISPR Gene Editing Papers This Year (2026)

As of November 2, 2026, “In vivo site-specific engineering to reprogram T cells” leads Most-Cited CRISPR Gene Editing Papers This Year with 45 citations. “CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia” is second and “Optimized lipid nanoparticles for pulmonary delivery of CRISPR/Cas9 targeting KRAS G12S in lung cancer” third.

🚫 No paid placement📡 Source: OpenAlex🕒 Updated November 2, 2026 ⓘ How we measure

Full ranking

1
🩺
In vivo site-specific engineering to reprogram T cells ↗ •🏆 Leader
William A. Nyberg et al. · Nature · 2026-03-18
45 citationsCitations
2
🩺
CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia ↗ •
Haydar Frangoul et al. · New England Journal of Medicine · 2026-04-01
23 citationsCitations
3
🩺
Optimized lipid nanoparticles for pulmonary delivery of CRISPR/Cas9 targeting KRAS G12S in lung cancer ↗ •
Moritz Marschhofer et al. · Journal of Controlled Release · 2026-01-06
9 citationsCitations
4
🩺
Gene Editing Therapy in Cardiovascular Disease: 2026 ACC Scientific Statement ↗ •
Amrut V. Ambardekar et al. · Journal of the American College of Cardiology · 2026-03-26
8 citationsCitations
6
🩺
Current global challenges and innovative strategies to combat antimicrobial resistance ↗ •
Manisha Sharma et al. · Discover Public Health · 2026-04-02
6 citationsCitations
7
🩺
Miniature and versatile genome regulation TnpB-ωRNA toolkits facilitate cancer immunotherapy ↗ •
Junlin Lu et al. · Nature Communications · 2026-04-01
6 citationsCitations
8
🩺
STING Ablation in T Cells Is Required for the Efficacy of STING Agonists in CAR-T Cell Immunotherapy of Pancreatic Cancer ↗ •
Ignazio Piseddu et al. · Gastroenterology · 2026-02-13
6 citationsCitations
9
🩺
CD44-targeted lipid nanoparticles for enhanced CRISPR/Cas9 delivery in cancer gene editing ↗ •
Ye Zeng et al. · Journal of Controlled Release · 2026-01-04
6 citationsCitations
10
🩺
CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial ↗ •
John F. DiPersio et al. · Nature Medicine · 2026-05-01
5 citationsCitations

How this ranking works

Ranked by citation count (OpenAlex) among research papers published this year whose title or abstract matches this topic. Citations build up over time, so the newest papers rank lower. For information only, not medical advice.

Methodology →

SourceOpenAlex
SignalCitations
Last updatedNov 2, 2026, 4:27 PM UTC
Top 10Citations of papers published this year

Frequently asked questions

What is #1 in Most-Cited CRISPR Gene Editing Papers This Year?

As of November 2, 2026, #1 is “In vivo site-specific engineering to reprogram T cells”.

How is this ranking measured?

Ranked by citation count (OpenAlex) among research papers published this year whose title or abstract matches this topic. Citations build up over time, so the newest papers rank lower. For information only, not medical advice.

How often is this chart updated?

Data is re-collected automatically and every page shows its last update date.

Can a brand pay to appear in this ranking?

No. There are no paid placements and no commercial influence on rank.

More rankings for you